BTK is a well‐known target for the treatment of leukaemia and lymphomas and is critical for B‐cell proliferation in cancer.[42, 43] Currently, all FDA approved BTK inhibitors are covalent inhibitors containing an acrylamide that reacts with Cys481. This evidence concerns the gene BTK and lymphoma.